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Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metasta-
sis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many
recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general
myofibroblast marker, and can be used to identify CAFs. This study investigates the prog-
nostic impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and cor-
relates their expression to 105 proteins investigated in the same cohort.
Methods
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were
constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-
SMA and explore their impact on survival and association with other tumor molecular mark-
ers in NSCLC patients.
Results
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043,
HR = 0.63 95% CI 0.40–0.99) was significantly associated with increased disease-specific
survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of
FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific
correlation patterns.
Conclusion
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLC-
SCC patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different
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subsets of fibroblasts and their associations with other tumor-related proteins diverge
according to histological subtype.
Introduction
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer associated death
worldwide, with both high incidence and mortality rates [1]. Current treatment strategies con-
sist of wide tumor resection with the supplement of radio- and/or chemotherapy for subgroups
of patients with poor prognosis [2]. NSCLC is a heterogeneous disease, including squamous cell
carcinoma (SCC) and adenocarcinoma (ADC) as the dominant histological subgroups, which
treatment-wise used to be considered a single entity. However, emerging evidence from molecu-
lar marker analyses indicate the molecular background of NSCLC subtypes to differ [3]. Exten-
sive analyses of genetic alterations have revealed distinct NSCLC subtypes that can be targeted
with modern therapeutic approaches. However, these new and exciting strategies have yet to be
implemented in an adjuvant setting to improve the overall survival of NSCLC patients [3].
Over the last two decades, an increasing awareness of cancer as a complex and heterogenous
disease has risen. This fact has shifted the focus of cancer research from a reductionist view
including only malignant cells to include also the supportive stromal tissue surrounding the
tumor. For colorectal, breast and lung cancer the prognostic impact of immune cells infiltrating
the intratumoral stroma is thought to supplement and even surpass the established TNM stag-
ing algorithms [4–6]. Another fundamental player in the stromal compartment is the cancer
associated fibroblasts (CAFs). Fibroblasts comprise a very heterogeneous and multi-functional
cell population, which plays important regulatory roles in wound healing, embryonic develop-
ment and cancer initiation and propagation [7]. In cancer, numerous studies have documented
the importance of reciprocal interactions between malignant cells and CAFs [7]. In addition,
CAFs regulate important elements in the tumor associated stroma including ECM, angiogene-
sis, recruitment and activation of immune cells and the recruitment of peripheral progenitor
cells [7,8]. The generic name “CAF” encompasses a diverse set of cells that may have different
origins and functions. Thus, the term "CAFs" may be referring to tumor resident fibroblasts,
activated fibroblast, peritumoral fibroblasts, myofibroblasts, pericytes and other mesenchymal
cells derived from circulating progenitors or after epithelial or endothelial trans-differentiation.
Traditionally, CAFs have been identified by their wide-spread expression of alpha-smooth
muscle actin (α-SMA), however, due to the notable cellular heterogeneity; α-SMA expression
alone will not identify all CAFs [7,8]. Hence, other CAF markers in use are vimentin, fibronec-
tin, fibroblast-specific protein 1 (FSP-1), fibroblast activation protein 1 (FAP-1) and PDGFR-
α/β [8,9]. FAP-1 is a membrane-anchored serine protease, which is selectively expressed by
stromal and mesenchymal cells during wound healing, fibrotic reactions, inflammatory condi-
tions and tumor development [8]. Because of the transient expression of this marker during
activation, FAP-1 has been used in many studies to identify activated tumor fibroblasts [8].
Several studies have associated the presence of different functional subsets of CAFs in pri-
mary NSCLC with adverse prognosis, including CAFα-SMA and CAFTGF-β in a cohort of mixed
NSCLC [10] and CAFPodoplanin in lung ADC [11–13] and SCC [14]. In addition, the presence
of CAFPodoplanin in lymph node metastases of nodal stage 2 lung SCC patients has been associ-
ated with a higher rate of mediastinal recurrence [15,16]. Only one small study (n = 59) has
investigated the presence of CAFFAP in NSCLC and found an association with worse prognosis
[17].
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We have previously evaluated 105 molecular tumor-related proteins in a cohort of unse-
lected resected stage I-IIIA NSCLC patients. The aim of this study was to investigate the prog-
nostic impact of CAFFAP and CAFα-SMA in NSCLC, and to correlate their presence with the
expression of other tumor molecular markers.
Material and Methods
1. Patients and Clinical Samples
Primary tumor tissue from 536 patients diagnosed with, and surgically resected for stage I-IIIA
NSCLC at the University Hospital of North-Norway and Nordland Central Hospital from
1990 through 2010 were included in this study. This represents an expansion and update of a
previously existing cohort including patients with the same criteria from 1990 through 2004
[18]. The included patients were staged according to the 7th edition of the UICC TNM classifi-
cation and classified according to the new pathological classification of lung cancer [19]. In
total 633 patients were registered from the hospital databases. Of these 97 were excluded from
the study due to: radiotherapy or chemotherapy prior to surgery (n = 15), other malignancy
within five years before NSCLC diagnosis (n = 39), inadequate paraffin-embedded fixed tissue
blocks (n = 25) and adenocarcinoma in situ (AIS), prior to 2011 classified as bronchoalveolar
carcinoma in situ (BAC)< 3 cm on revision (n = 18). Thus 536 with complete medical records
and available formalin-fixed paraffin-embedded (FFPE) tissue blocks were eligible.
This report includes follow-up data as of October 1st 2013. The median follow-up of survi-
vors was 73 months (range 0–267).
2. Micro-array Construction
All patient samples were reviewed independently by two pathologists. The most representative
areas, containing both tumor and intratumoral stroma, were marked on the hematoxylin and
eosin (H/E) slides and sampled for the tissue micro-array (TMA) blocks. The TMAs were
assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, USA).
The detailed methodology has been reported previously [20]. Briefly, we used a 0.6 mm stylet
to sample four replicate cores from each of the study specimens.
To include all core samples, 12 TMA blocks were constructed. Multiple 4-μm sections were
cut with a Micron microtome (HM355S) and stained by specific antibodies for immunohis-
tochemistry (IHC) analysis.
3. Immunohistochemistry
Immunohistochemistry (IHC) assays for FAP-1were performed on the Ventana Discovery-
Ultra automated immunostainer (Ventana Medical Systems, Tucson, AZ). Deparaffinization
and on-board antigen retrieval were performed for 24 minutes at approximately 100°C with
CC1 reagent, which is an EDTA-based proprietary Ventana solution (pH 8.0–8.5). FAP-1anti-
rabbit polyclonal antibody (Ab53066, Abcam, dilution 1/50) was applied and incubated for 32
minutes. Slides were developed using Ultramap anti-rabbit HRP (Cat#760–4315, Ventana) and
were detected using ChromoMap DAB (Cat#760–159, Ventana).
IHC assays for α-SMA were stained on Ventana Benchmark-ultra (Ventana Medical Sys-
tems Inc.). Epitope retrieval was accomplished with CC1 solution for 8 minutes. The α-SMA
mouse monoclonal antibody (cat#760–2833, Ventana, clone 1A4) was incubated at 37° for 32
minutes and detected by using the Ultraview DAB Detection kit. Finally, to visualize the nuclei,
slides were counterstained with Ventana Hematoxylin II reagent for 8 minutes, followed by a
Bluing reagent for 4 minutes.
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Two different controls for our staining method were applied. Firstly, control staining of the
sections with an isotype-matched control antibody without the primary antibody. Secondly,
multiple organ tissue micro-array as positive and negative tissue controls were used to verify
the specificity of the staining in every staining procedure. The positive tissue controls com-
prised normal liver and breast carcinoma for FAP-1 and appendix and vessel wall for alpha-
SMA; Negative tissue controls were samples of normal pancreas, lung, breast, tonsil and kidney
for both Fap and α-SMA.
4. Antibody validation
Mouse-monoclonal anti-human α-SMA antibody was purchased from Ventana (cat#760–
2833, Ventana, clone 1A4). This antibody has been subjected to extensive quality-control and
validation procedures by the manufacturer which ensures proper and specific staining of the
antigen in paraffin-embedded tissue. Polyclonal rabbit anti-human FAP-1 antibody was pur-
chased from abcam (Cat.#:ab53066). Specificity test of this antibody was done in-house by
western blot. Antibody was tested against whole cell extracts from several CAF cell lines and
from the lung tumor cell line A549. Western blots showed a single band of about 70 KDa in
protein extracts from CAFs (Fig 1D). This antibody has previously been tested on isolated
CAFs by IHC [21].
5. Scoring of Immunohistochemistry
Representative and viable tissue sections were reviewed using a (Leica DM 2500" Leica Micro-
systems Ltd., CH9435 Heerbrugg, Switzerland). Based on initial review, author Al-Saad estab-
lished a semi-quantitative score for each marker. The slides were scored for FAP-1 in the total
material and α-SMA in the updated material (cases from 2005 through 2010) by authors
Rakaee Khanehkenari and Martinez. α-SMA had previously been scored for cases from 1990
through 2004. The dominant staining intensity in percentage of positive cells in the intrae-
pithelial stromal compartment was scored as follows: 0 = no staining, 1 = 1–10%, 2 = 11–50%
and 3 => 50%. When assessing a given core, the observers were blinded to the scores of other
variables and to outcome. We did not observe any staining of tumor epithelial cells for either
α-SMA nor FAP-1. This is is similar to reports from other studies [22].
High expression was defined as the optimal cut-off point discriminating the high/low
groups according to survival. High expression was defined as a score> 0.5 (FAP-1) and>2 (α-
SMA).
6. Statistical Methods
All statistical analyses were conducted using RStudio 0.98.1091 with R version 3.1.1.1[23] and
libraries "survival"[24], "car"[25], "ggplot2"[26], "gridExtra"[27], "Hmisc"[28] and "irr"[29].
The IHC scores from each observer were compared for interobserver reliability using a two-
way random effects model with absolute agreement definition and Cohens kappa-statistics
with equal weights. The intraclass correlation coefficient (reliability coefficient) and Cohen's
kappa were obtained from these results.
The Chi-square and Fischer's Exact tests were used to examine the association between
molecular marker expression and clinipathological variables and to check whether there were
differences in marker expression in the original and updated patient cohort. Spearman`s rank-
correlation was used to examine the associations between marker expressions. Due to the large
number of correlation analyses, Bonferroni corrections for P-values were conducted for these
analyses.
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Univariate survival analyses were done using the Kaplan-Meier method. Statistical differ-
ences between survival curves were assessed by the log-rank test. Disease-specific survival
(DSS) was defined as the time from surgery to lung cancer related death. Multivariate analysis,
using the Cox proportional hazards model, was carried out to assess the independent value of
pretreatment variables in the presence of other variables. Only variables with P< 0.25 from
the univariate analyses or otherwise thought to be important were explored in the Cox regres-
sion analysis.
The significance level used for survival analyses was P< 0.05
7. Ethical Clearance
The study was approved by the Regional Committee for Medical and Health Research Ethics
(Northern Norway, UNN: protocol ID: 2011/2503) and the need for consent was waived
unnecessary. The collection and storing of the clinical database was approved by the National
Data Inspection Board. The reporting of clinicopathological variables, survival data and bio-
marker expression was conducted in accordance with the REMARK guidelines.
Results
1. Clinicopathological Variables
Clinicopathological variables are summarized in Table 1. Median age at time of diagnosis was
67.2 years and 32% of the patients were female. The histological distribution of the 536 cases
Fig 1. A) IHC analysis of TMA cores from NSCLC patients representing different stromal cell scores for
expression of FAP-1 and α-SMA. I) Low stromal FAP-1; II) High stromal FAP-1; III) Low stromal α-SMA; IV)
High stromal α-SMA. B) TMA control of healthy lung tissue showing strong FAP-1 positivity in normal lung
macrophages, C) TMA control of healthy lung tissue showing some weak to intermediate α-SMA staining, D)
Western blot for FAP-1 showing one clear 70 kDa band. Abbreviations: FAP-1, Fibroblast activating protein;
α-SMA, alpha-smooth muscle actin.
doi:10.1371/journal.pone.0134965.g001
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Table 1. Prognostic clinicopathological and FAP-1 and α-SMA as predictors of disease-specific survival in resected non-small-cell lung cancer




















Age 0.711 0.654 0.505
65 227
(42)
57 127 1 106
(37)


















Gender 0.026 0.108 0.050
Female 170
(32)
63 190 1 73
(25)


















ECOG 0.015 0.158 0.003
0 310
(58)
62 235 1 158
(55)



























12(6) 17 25 3.25
(0.96–
11.03)
Smoking 0.039 0.19 0.68
Previous 17
(3)






























Weightloss 0.961 0.689 0.536
<10% 480
(90)
58 127 1 256
(89)
























63 190 1 197
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Margins 0.129 0.252 0.018
Free 489
(91)
59 190 1 257
(89)
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12(6) 0 35 2.33
(0.81–
6.69)
Tstage <0.001 <0.001 <0.001
I 168
(31)
72 235 1 83
(29)

































IV 6(1) 20 15 4.89
(0.89–
26.9)
3(1) 0 10 17.41
(0.22–
1371.77)
2(1) 50 13 1.76
(0.23–
13.27)
Nstage <0.001 <0.001 <0.001
0 364
(68)
69 235 1 198
(69)

































Pstage <0.001 <0.001 <0.001
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(48)
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(44)














































Differentiation <0.001 0.033 0.006
Poor 231
(43)
49 51 1 104
(36)
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were 289 squamous cell carcinomas (SCC), 201 adenocarcinomas (ADC) and 46 undifferenti-
ated carcinomas (NOS). In addition to surgical resection, 64, 89 and 12 patients received adju-
vant radiotherapy, chemotherapy and radiochemotherapy, respectively.
2. Interobserver Reliability and Tests for Differences in Expression
The intraclass correlation coefficients and Cohen's kappa were 0.759 (P< 0.001) and 0.598
(P< 0.001) for FAP-1 and 0.790 (P< 0.001) and 0.657 (P< 0.001) for α-SMA. No difference
in expression for FAP-1 (P = 0.284) or α-SMA (P = 1.000) was observed according to time
period (original vs updated cohort).
3. Survival Analyses
Table 1 summarizes the impact of clinicopathological variables and investigated markers in the
overall group and stratified into histological subgroups. Fig 2 panels A-F shows the survival
curves of FAP-1 and α-SMA low vs high expression in the overall cohort and stratified into
SCC and ADC subgroups. High expression of FAP-1 was a significant positive marker for sur-
vival in the SCC subgroup (P = 0.043). Neither FAP-1, nor α-SMA expression in tumor stroma
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(80)


















FAP-1 0.070 0.043 0.986
Low 98
(18)
51 71 1 52
(18)



















α-SMA 0.597 0.220 0.797
Low 362
(68)
57 127 1 198
(69)



















Abbreviations: SCC, squamous-cell carcinoma; ADC, adenocarcinoma; NOS, Not otherwise specified; FAP-1, Fibroblast activating protein; α-SMA, alpha-
smooth muscle actin.
doi:10.1371/journal.pone.0134965.t001
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4. Expression of FAP-1 and α-SMA and their Correlations
FAP-1 and α-SMA expression was localized in the cytoplasm of stromal cells (Fig 1A). Of note,
FAP-1 expression was not restricted to fibroblast-like cells as intratumoral and healthy lung tis-
sue macrophages were strongly stained by the antibody (Fig 1B). However, when assessing the
cores, macrophage expression of FAP-1 was not taken into consideration. S1 Table summarizes
the associations of FAP-1 and α-SMA with clinicopathological markers. After corrections for
multiple testing no significant associations were observed.
Table 2 summarizes the significant correlations of FAP-1 and α-SMA with tumor-related pro-
teins previously analyzed in this patient cohort. S2 Table names all markers included in the corre-
lation analyses (n = 105). After corrections for multiple testing, significant correlations were
observed between FAP-1 and the following markers: stromal expression of HIF2 (r = 0.26),
LDH5 (r = 0.25), FOXP3 (r = 0.23), CSF1R (r = 0.26) and miR21 (r = 0.27) and tumor cell expres-
sion of p21 (r = 0.30) in the total cohort; stromal expression of CSF1R (r = 0.29) and mir21
(r = 0.31) in the SCC subgroup; stromal expression of HIF2 (r = 0.42) and tumor cell expression
of MCT3 (r = -0.42) in the ADC subgroup. α-SMA showed no significant correlations, neither in
the whole material, nor in subgroups, after corrections for multiple testing was conducted.
Discussion
The present study was initiated to explore the potential prognostic impact of CAFs in NSCLC,
and the existing correlations of these cells with other relevant tumor biological markers. In a
Fig 2. Disease-specific survival curves for A) FAP-1 in the overall cohort; B) FAP-1 in SCC; C) FAP-1 in ADC; D) α-SMA in the overall cohort; E) α-
SMA in SCC; F) α-SMA in ADC. Abbreviations:SCC, squamous-cell carcinoma; ADC, adenocarcinoma; FAP-1, Fibroblast activating protein; α-SMA, alpha-
smooth muscle actin.
doi:10.1371/journal.pone.0134965.g002
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Table 2. Significant Spearman rank-correlations with R-values > 0.20 between tumor and stromal cell expression of FAP-1 or α-SMA in TMA sam-
ples from NSCLC patients (n = 536 for correlations with CD3 and correlations between FAP-1 and α-SMA and 326 for the remaining correlations)
and in subgroup analyses of NSCLC according to histology (SCC n = 289 for correlations with CD3 and correlations between FAP-1 and α-SMA
and 191 for the remaining correlations, ADC N = 201 for correlations with CD3 and correlations between FAP-1 and α-SMA and 95 for the remaining
correlations).
All cases SCC ADC
FAP-1 α-SMA FAP-1 α-SMA FAP-1 α-SMA






CXCL16 0.21*** 0.26*** Ch
DLL4 0.26* Ch
bAkt 0.21* EMT
cAkt 0.21*** 0.21* EMT
ERK3 0.28*** -0.21* EMT
Igf1 0.21** EMT
Masson's trichrome 0.2*** 0.26*** EMT
NfκB 0.22** 0.24* EMT
HIF2 0.26# 0.22** 0.42# Hyp
LDH5 0.25# 0.25*** Hyp
CD3 0.21** Imad
FOXP3 0.23# 0.23* Imad
CD138 0.23* Imin
CD56 0.21* Imin
Cox 0.21*** 0.23* Imin
CSF1R 0.26# 0.29# Imin
MCT1 0.21*** 0.22** 0.27* Met
MCT2 -0.25* Met
MCT4 0.26* Met
miR21 0.27# 0.31# miR
miR210 0.21** miR
Igfbp -0.3** other
Ki67 -0.22** 0.28* other
Notch4 0.25* other
Par6 0.21** other




Vessel co option 0.21* Ang
Bad in cytoplasm -0.21** Ap
Bad in nucleus -0.22** Ap






Cancer Associated Fibroblasts in NSCLC
PLOSONE | DOI:10.1371/journal.pone.0134965 August 7, 2015 10 / 15
recent review, Cortez et al. highlighted four functional CAF subsets according to expression of
effector molecules and receptors; CAFFAP, CAFFSP1, CAFPDGFR-α and CAFPDGFR-β [8]. Signifi-
cant efforts have been devoted to explore the role of CAF subtypes in NSCLC. The most stud-
ied subtype, CAFPodoplanin, has been associated with shorter overall survival for both ADC and
SCC lung cancer patients [11–14] and their presence in mediastinal lymph-node metastases
increases the risk of mediastinal recurrence [15,16]. Due to CAF heterogeneity and the lack of
a single universal marker, we chose to identify CAFs by two of the most widely used markers
that exclude quiescent fibroblasts from CAFs, namely FAP-1 and α-SMA. In contrast to previ-
ous reports on CAFs and NSCLC, we find that CAFFAP are predictors of favorable prognosis in
the SCC subgroup. Intriguingly, in our study FAP-1 and α-SMA expression do not correlate
with each other, indicating that these markers identify different CAFs subtypes. Lastly, our
study uncovers interesting correlations between CAFFAP and other tumor molecular markers
that aid in understanding the mechanisms behind the observed impact in prognosis. To our
knowledge this study represents the largest evaluation of CAFFAP and CAFα-SMA in NSCLC.
1. CAFFAP in NSCLC
Liao et al. explored the role of CAFFAP in a small series of 59 NSCLC patients and found higher
levels of FAP expressing stromal cells to be an independent indicator of poor overall survival
[17]. In contrast, we found, in a larger patient cohort, the presence of CAFFAP to predict
increased disease-specific survival in SCC, but not in ADC patients. The defined role of CAFFAP
is poorly understood and their presence has been investigated in other tumor groups with differ-
ing results. In invasive ductal carcinoma of the breast, CAFFAP are associated with increased sur-
vival, while in ADC of the pancreas and rectum they are associated with decreased survival [30–
32]. These results, in line with our study, indicate that CAFFAP interact with tumor cells and
other players in the tumor micro-environment in differential ways according to the context,
Table 2. (Continued)
All cases SCC ADC





miR21 0.22*** 0.26*** miR
miR182b 0.2*** 0.25* miR
Ki67 0.25* other
Abbreviations: SCC, squamous-cell carcinoma; ADC, adenocarcinoma; FAP-1, Fibroblast activating protein; α-SMA, alpha-smooth muscle actin; Ang,
Angiogenin; bFGF, basic fibroblast growth factor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; CXCL, C-X-C
motif ligand; DLL, Delta-Like; ERK, extra-cellular signal regulated kinase; Igf; insulin growth factor; NfκB, nuclear factor kappa-light-chain-enhancer of
activated B cells; HIF, hypoxia-induced factor; LDH, lactate dehydrogenase; CD, cluster of differentiation; FOXP3; forkhead box P3; Cox, cyclo-
oxygenase; CSF1R, colony-stimulating factor 1 receptor; MCT, monocarboxylate transporter; miR, micro RNA; Igfbp, insulin growth factor binding protein;
Par, partitioning-defective; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; Bad, BCL-2 associated death
promoter; p21, protein 21; SKB,SHK1 binding protein; PHD, prolyl hydroxylase-domain.
*significant at p > 0.05,
**significant at p > 0.01,
***significant at p > 0.001,
# significant after Bonferroni correction for multiple tests
doi:10.1371/journal.pone.0134965.t002
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tumor stage and tissue of origin. The difference between our study and the Liao study could be
explained by their inferior number of included patients, the use of whole-slide examinations vs
TMA core samples, or differences in the patient cohorts otherwise unaccounted for.
Obviously, our TMA based study cannot directly explain the mechanisms of these observed
effects. Nevertheless, extensive correlation analyses (Table 2) in our patient cohort reveal strong
positive associations between CAFFAP and stromal expression of colony-stimulating factor
receptor 1 (CSF1R) and micro-RNA 21 (miR21) in SCC and stromal expression of hypoxia-
induced factor 2 (HIF2) in ADC and strong negative association with tumor cell expression of
monocarboxylate transporter 3 (MCT3) in ADC. Stromal CSF1R could be expressed both in
macrophages and in myeloid dendritic cells (DC) [33]. The presence of type M1 cytotoxic mac-
rophages could explain the survival benefit we observe in CAFFAP SCC patients, by macrophages
directly targeting tumor cells. CSF1R positive DCs are able to take up antigen and their presence
may indicate a local immune-response [33]. miR21 is generally described as an onco-miR and is
expressed in most solid cancers [34]. A recent study has established a link between miR21
expression and CAF formations and could explain the positive correlation seen in our cohort of
SCC patients [35]. We have previously identified high stromal miR21 expression to predict poor
survival for a subset of NSCLC patients [36]. In this study the low miR21 expressing group com-
prised only 21 patients which might possibly explain the observed increased survival in the SCC
subgroup, even though a moderately strong correlation with miR21 is observed.
Previous results have shown high stromal expression of HIF2 to be a favorable indicator of
prognosis of SCC, but not ADC, while tumor cell expression of MCT3 was unrelated to prog-
nosis regardless of histological subgroups [37,38].
Strategies have been developed to utilize the presence FAP-expressing stromal cells in the
treatment of cancer. These can be divided into two categories i) those that targets and neutral-
izes CAFFAP directly and ii) those that utilize FAP expression in tumor stromal cells to deliver
a drug to the tumor site [39–43]. Our results indicate that for NSCLC patients, and especially
in the SCC subgroup, the first approach might prove detrimental.
2. CAFα-SMA in NSCLC
α-SMA is generally accepted as a myofibroblast marker, although the labeling is unspecific and
other cell-types such as pericytes may also be stained [8]. Chen et al. explored the roles of
CAFα-SMA and CAFTGF-β in a small cohort of 78 NSCLC patients of all stages and histologies
using whole tumor tissue slides. They found CAFα-SMA to be an independent indicator of
adverse outcome [10]. In our study, the presence of CAFα-SMA did not show any prognostic
information, neither in the overall population, nor in subpopulations according to histology.
The difference in outcome could be explained by the different approaches used (whole slide vs
TMA) or by the different numbers of patients in the cohorts. Furthermore, the etiology of the
lung cancer cases could also be different. Assuming that Chen et al. mainly included patients
from the Suzhou region, which is a densely populated and highly industrialized area, it is con-
ceivable that the study included a larger number of patient with smoking-unrelated lung can-
cer. Unfortunately, the Chen study did not include information about smoking status. In
contrast, our study recruited patients from Northern-Norway, a sparsely populated region with
hardly any polluting industry, and only 18 out of 536 of the included patients had never
smoked. It would be interesting to explore how CAFα-SMA reacts to different stimuli (eg. smok-
ing vs industrial pollution).
Of interest, no significant correlations (after correction for multiple testing) were observed
between the presence of CAFα-SMA and other tumor-related proteins previously investigated in
our patient cohort.
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Conclusion
In NSCLC, our results indicate that the presence and prognostic significance of CAF subtypes
differ between histological subgroups and that the presence of CAFFAP may be beneficial for
the survival of NSCLC SCC patients. These results are in contrast to one other small study of
CAFFAP in NSCLC. This discrepancy is important as CAFFAPtargeting strategies are being
developed. The utilization of such strategies in NSCLC patients, especially in the SCC sub-
group, should be approached with diligence until these results are further validated and
explored in in-vitro and in in-vivo tumor models of both SCC and ADC NSCLC.
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